Success in treating mild chronic hepatitis C: different outcomes - new guidelines?

被引:3
作者
Rosenberg, WMC [1 ]
机构
[1] Univ Southampton, Southmead Gen Hosp, Southampton SO16 6YD, Hants, England
关键词
hepatitis C; mild disease; treatment;
D O I
10.1097/00042737-200206000-00003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Limited knowledge of the natural history of chronic hepatitis C suggests that patients with mild histological changes on liver biopsy are at low risk of developing liver related morbidity or mortality, Patients with mild disease have been excluded from the large trials of treatment for hepatitis C and consequently guidelines recommend that they are excluded from treatment. However, as the probability of a beneficial response to treatment increases with improvements in antiviral therapy so the threshold for treatment falls. Trials reporting good responses to treatment in patients with mild disease support the case for widening access to treatment. Increasing recognition that chronic hepatitis C infection can lead to impairment of quality of life that is independent of liver histology is likely to result in more patients with mild hepatitis seeking treatment, more clinical trials that include patients with milder stages of liver disease, and greater enthusiasm for their inclusion in treatment guidelines. Eur J Gastroenterol Hepatol 14:595-597 (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:595 / 597
页数:3
相关论文
共 15 条
[1]  
[Anonymous], 1999, J Hepatol, V30, P956
[2]   Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C [J].
Bennett, WG ;
Inoue, Y ;
Beck, JR ;
Wong, JB ;
Pauker, SG ;
Davis, GL .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) :855-+
[3]   Clinical guidelines on the management of hepatitis C [J].
Booth, JCL ;
O'Grady, J ;
Neuberger, J .
GUT, 2001, 49 :I1-I21
[4]   Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C [J].
Buti, M ;
Casado, MA ;
Fosbrook, L ;
Wong, JB ;
Esteban, R .
JOURNAL OF HEPATOLOGY, 2000, 33 (04) :651-658
[5]   Management of chronic hepatitis C: A consensus [J].
Dienstag, JL .
GASTROENTEROLOGY, 1997, 113 (02) :375-375
[6]   Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis [J].
Foster, GR ;
Goldin, RD ;
Thomas, HC .
HEPATOLOGY, 1998, 27 (01) :209-212
[7]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965
[8]   The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity [J].
McHutchison, JG ;
Ware, JE ;
Bayliss, MS ;
Pianko, S ;
Albrecht, JK ;
Cort, S ;
Yang, I ;
Neary, MP .
JOURNAL OF HEPATOLOGY, 2001, 34 (01) :140-147
[9]   Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C [J].
Poynard, T ;
McHutchison, J ;
Davis, GL ;
Esteban-Mur, R ;
Goodman, Z ;
Bedossa, P ;
Albrecht, J .
HEPATOLOGY, 2000, 32 (05) :1131-1137
[10]   Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus [J].
Poynard, T ;
Marcellin, P ;
Lee, SS ;
Niederau, C ;
Minuk, GS ;
Ideo, G ;
Bain, V ;
Heathcote, J ;
Zeuzem, S ;
Trepo, C ;
Albrecht, J .
LANCET, 1998, 352 (9138) :1426-1432